Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
0.964
-0.016 (-1.66%)
At close: Dec 20, 2024, 4:00 PM
0.990
+0.026 (2.74%)
After-hours: Dec 20, 2024, 7:36 PM EST
Company Description
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States.
The company’s lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020.
Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Atossa Therapeutics, Inc.
| Country | United States |
| Founded | 2009 |
| IPO Date | Nov 8, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Steven Quay |
Contact Details
Address: 107 Spring Street Seattle, Washington 98104 United States | |
| Phone | 206 588 0256 |
| Website | atossatherapeutics.com |
Stock Details
| Ticker Symbol | ATOS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001488039 |
| CUSIP Number | 04962H506 |
| ISIN Number | US04962H5063 |
| Employer ID | 26-4753208 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Steven C. Quay FCAP, M.D., Ph.D. | Chairman, Chief Executive Officer and President |
| Heather Rees C.P.A. | Chief Financial Officer |
| Delly Behen P.H.R. | Senior Vice President of Administration and Human Resources |
| Michael Parks | Vice President of Investor and Public Relations |
| Dr. Richard Graydon M.D., Ph.D. | Interim Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 10, 2024 | 8-K | Current Report |
| Nov 19, 2024 | 8-K | Current Report |
| Nov 19, 2024 | 424B5 | Filing |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 4, 2024 | 8-K | Current Report |
| Oct 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |